About Angelini Ventures
Angelini Ventures is a venture capital firm founded in 2021. It is primarily based out of Rome, Italy. As of Oct 2026, Angelini Ventures is an active investor, having invested in 31 companies, with 9 new investments in the last 12 months. It primarily invests in Series A round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and HealthTech. Most recently it participated in the $***** Series D round of Medical Microinstruments Overall, Angelini Ventures portfolio has seen 1 acquisition, namely Noctrix Health. A lot of funds co-invest with Angelini Ventures, with names like Kurma Partners sharing a substantial percentage of its portfolio. Angelini Ventures has team of 21 people including 10 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Seed, Series A & 2 more
Portfolio Acquisitions
Portfolio Soonicorns
Deals in last 12 months
Angelini Ventures' List of Top Investments
Angelini Ventures has a portfolio of 31 companies. Their most notable investments are in Therini Bio and Cour Pharma.Their portfolio spans across United States, Italy, France and 9 more locations. They have invested in Life Sciences, High Tech, HealthTech and 4 other sectors, across stages such as Seed, Series A and 2 more. Here is the list of top investments by Angelini Ventures:
Provider of robotic platform using micro instruments for surgery. It uses a robotic platform that enables the use of microsurgical instruments for reconstruction procedures after traumatic injuries and tumor removal. The surgeons use the robotic platform which scales down the hand movements to the movements of the instruments during surgery. It claims that the product is the smallest robotic wrist.
Key facts about Medical Microinstruments
- Founded Year: 2015
- Location: Calci (Italy)
- Annual Revenue: €1M - €10M as on Dec 31, 2022
- Stage: Series D
- Total Funding till date: $354M
- Employee Count: 316 as on Sep 30, 2026
- Investors: Fidelity Investments, RA Capital Management and 15 Others
- Latest Funding Round: Series D, Oct 08, 2026, $*****
- Highlight: Editors' Pick
Noctrix Health is engaged in developing prescription-grade wearable therapeutic devices. They are developing a medical device for treating chronic neurological disorders, especially to treat the symptoms of restless leg syndrome.
Key facts about Noctrix Health
- Founded Year: 2016
- Location: San Francisco (United States)
- Stage: Acquired
- Total Funding till date: $90.5M
- Employee Count: 176 as on Sep 30, 2026
- Investors: Sectoral, Zühlke and 15 Others
- Latest Funding Round: Series C, Aug 29, 2025, $*****
- Highlight: Acquired
3. Nuevocor
Developer of genetic medicines for treating rare heart muscle conditions. These therapies target underlying mechanical defects in heart tissue to address disease progression. The focus remains on creating treatments for specific genetic cardiomyopathies that currently lack effective therapeutic options.
Key facts about Nuevocor
- Founded Year: 2021
- Location: Singapore (Singapore)
- Stage: Series B
- Total Funding till date: $80.6M
- Employee Count: 29 as on Aug 31, 2026
- Investors: Kurma Partners, Boehringer Ingelheim Venture Fund and 7 Others
- Latest Funding Round: Series B, May 06, 2025, $*****
- Highlight: Editors' Pick
Developer of therapeutics for multiple diseases. It offers gene therapies using ultracompact Cas proteins which modulate gene expression without cutting DNA. The company's platform leverages the power of CRISPR/Cas9 gene editing to target specific genes and achieve therapeutic outcomes. The pipeline includes EPI-321 for facioscapulohumeral muscular dystrophy, EPI-221, EPI-224 for genetic disorder, EPI 114 and EPI 111 for petinas pigmentosa.
Key facts about Epicrispr Bio
- Founded Year: 2018
- Location: San Francisco (United States)
- Stage: Series C
- Total Funding till date: $245M
- Employee Count: 52 as on Aug 31, 2026
- Investors: Fidelity Investments, Janus Henderson Investors and 10 Others
- Latest Funding Round: Series C, May 04, 2026, $*****
- Highlight: Editors' Pick
Developer of therapeutics for the treatment of rare diseases. It offers an in-silico platform that enables the design of small molecules that stabilizes misfolded proteins to treat rare diseases. It offers computational drug discovery engine called Revenir which captures the biophysical changes caused by mutations in proteins. It examines surface features and numerous biophysical descriptors of both the mutated and wild-type proteins. It offers a lead candidate CGX-926 for obesity.
Key facts about Congruence Therapeutics
Angelini Ventures' Year-on-Year Investment Trends
Angelini Ventures has invested in 31 companies over the last 5 years, with an average of 5 new investments annually in the last 5 years. In 2025, it made 11 investments, while as of Oct 2026, it has made 9 investments in this year. Its most recent first time investment was in Rougetx and most recent follow-on round was in Medical Microinstruments.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 7 | 2 | 9 |
2025 | 9 | 2 | 11 |
2024 | 3 | 1 | 4 |
2023 | 5 | 0 | 5 |
2022 | 3 | 0 | 3 |
2021 | 1 | 0 | 1 |
Angelini Ventures' Investments by Stage
Angelini Ventures has made 9 investments in Seed stage with an average round size of $10.9M, 9 investments in Series A stage with an average round size of $54.3M, 5 investments in Series B stage with an average round size of $45.1M and 5 investments in Series C stage with an average round size of $68.1M.Stage of entry | No. of Investments |
|---|---|
Seed | 9 |
Series A | 9 |
Series B | 5 |
Series C | 5 |
Note: We have considered here, only first round of investments
Angelini Ventures' Investments by Sector
Angelini Ventures has a diverse portfolio, with companies operating in the Life Sciences, HealthTech, High Tech, Consumer and Enterprise Applications. Notably, it has invested in 26 Tech companies, 23 Enterprise (B2B) companies, 7 Tech hardware companies and at least 6 companies focusing on Consumer (B2C).Sector | No. of Investments |
|---|---|
Life Sciences | 21 |
HealthTech | 7 |
High Tech | 6 |
Consumer | 4 |
Enterprise Applications | 3 |
Others | 7 |
Note: We have considered here, only first round of investments
Angelini Ventures' Investments by Geography
Angelini Ventures has made most investments in United States (10), followed by Italy where it has made 4 investments.Country | No. of Investments |
|---|---|
United States | 10 |
Italy | 4 |
Denmark | 2 |
France | 2 |
Switzerland | 2 |
Others | 8 |
Note: We have considered here, only first round of investments
Angelini Ventures' recent investments
Angelini Ventures has made 9 investments in 2026 so far. Medical Microinstruments and Rougetx are the latest among them.Here are the most recent investments by Angelini Ventures:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Oct 08, 2026 | Italy | Series D | 7176 | [+1] | |
Oct 06, 2026 | - | Series A | 9520 | ||
Sep 29, 2026 | - | Seed | 4202 | [+6] | |
Sep 16, 2026 | Italy | Series C | 1101 | ||
Jul 07, 2026 | United States | Series B | 9973 | [+5] |
Acquired companies in Angelini Ventures' Portfolio
1 company from Angelini Ventures' portfolio has been acquired. The most recent acquisition was Noctrix Health in Apr 2026 by ResMed for $*****.Here are Angelini Ventures' portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Apr 30, 2026 | Jan 16, 2024 | Series C | 7139 |
Team profile of Angelini Ventures
Angelini Ventures has a team of 21 members including 10 Partners and 5 Principals located in United States, Italy and 5 more locations. Angelini Ventures' team sits on the board of 6 companies.Here is a list of top team members in Angelini Ventures:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | Munich | SNIPR Biome, STipe Therapeutics and 1 more | ||
Partner | Milan | - | - | |
Partner | Italy | - | ||
Partner | Singapore | - | ||
Partner | Italy | - | - | |
Partner | New York City | - | - | |
Partner | Cambridge | - | ||
Partner | Lausanne | - | ||
Partner | Boston | - |
Co-investors of Angelini Ventures
Over the past 5 years, 200 investors have co-invested in Angelini Ventures's portfolio companies. This includes funds and angels.
- Invested before Angelini Ventures: RA Capital Management, HHS and 57 others have invested in rounds before Angelini Ventures. There are 2 companies where RA Capital Management has invested before Angelini Ventures and 2 companies where HHS has invested before Angelini Ventures.
- Top Co-investors of Angelini Ventures: 116 investors entered a company along with Angelini Ventures. These include investors like Kurma Partners (6 companies).
- Invested after Angelini Ventures: A total of 25 investors have invested in Angelini Ventures's portfolio after their investments. Top Investors include S3 Ventures (1 company), BVF (1 company) and Bridge Bank (1 company).
Recent News related to Angelini Ventures
•
Angelini Ventures and EIB Co-Lead $58 Million Series A in Rouge Therapeutics for Rare Vascular Disease TreatmentGlobeNewswire•Oct 06, 2026•Angelini Ventures, Rougetx
•
EIB and Angelini Ventures Partnership Reaches €48.5 Million in InvestmentsGlobeNewswire•Sep 16, 2026•Angelini Ventures, European Investment Bank
•
Angelini Ventures Invests in Handspring Health's $19 Million Series B to Expand Access to High-Quality Mental Health CareGlobeNewswire•Jul 08, 2026•Angelini Ventures, Handspring, RPS Ventures, Serenis
•
Resmed Completes Acquisition of Noctrix Health, Expanding Clinical Sleep Health PortfolioAgencia EFE•Jun 01, 2026•ResMed, Noctrix Health, Angelini Ventures
•
NUCLIDIUM AG Announces Closing of Series B Extension, Raising Total Round to CHF 105 MillionGlobeNewswire•May 27, 2026•Angelini Ventures, Nuclidium, DeepTech & Climate Fonds, Neva SGR and 5 others
•
Angelini Ventures Leads £17 Million Series A for Hypervision Surgical to Advance AI-Assisted SurgeryYahoo•Apr 29, 2026•Angelini Ventures, Hypervision Surgical, IP Group, Heal Capital and 6 others
•
Laigo Bio Raises €11.5M in Seed FinancingFinSMEs•Dec 04, 2025•Laigo Biotechnology, Kurma Partners, Curie Capital, Argobio and 3 others
•
EIB and Angelini Ventures sign €150M agreement to fund European startupsGlobeNewswire•Dec 01, 2025•Angelini Ventures, European Investment Bank, STMicroelectronics
•
European Investment Bank Provides EUR 35 Million Venture Debt Financing to Sidekick HealthGlobal Legal Chronicle•Nov 27, 2025•SidekickHealth, European Investment Bank, Angelini Ventures
•
London’s CoMind Raises €85M To Revolutionize Non-invasive Brain MonitoringStartup Rise EU•Oct 20, 2025•CoMind, GE HealthCare, Angelini Ventures, Plural and 2 others
